LYVE1 Monoclonal Antibody (ALY7), eFluor™ 450, eBioscience™, Invitrogen™

Description

• Description: The monoclonal antibody ALY7 recognizes mouse LYVE-1, a transmembrane glycoprotein with similarity to CD44
• The extracellular domain contains a conserved hyaluro binding domain also found in CD44
• Expression is found on lymphatic and liver endothelial cells and some populations of macrophages
• The lymphatic system is responsible for transporting proteins and cells (especially dendritic cells) to tissues throughout the body, thereby acting as immune surveyors
• LYVE-1 is one characteristic protein, along with podoplanin, PROX-1, Tie-2 and VEGFR-3, that is expressed on lymphatic endothelial cells (LECS)
• The ligand for LYVE-1 is hyaluro, a large mucopolysaccharide
• Although LYVE-1 can bind hyaluro in vitro, the site for ligand binding in vivo is masked by sialyated O-linked glycan chains
• It is postulated that binding to ligand requires modification/unmasking to expose the binding site
• The development and remodeling of the endothelium after injury is an area of extensive study
• When transplanted, hematopoietic stem cells (HSCs) can give rise to LECs that integrate into the endothelium in normal and metastatic tissue
• Applications Reported: This ALY7 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This ALY7 antibody has been tested by flow cytometric analysis of BAF3 cell line transfected with LYVE-1
• This may be used at less than or equal to 0.5 μg per test
• LYVE1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall
• The deduced amino acid sequence of LYVE1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module, the prototypic HA binding domain of the Link protein superfamily
• Like CD44, the LYVE1 molecule binds both soluble and immobilized HA
• However, unlike CD44, the LYVE1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels
• Hence, LYVE1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves
• LYVE1 is a type I integral membrane glycoprotein
• LYVE-1 is expressed primarily on lymphatic vessel endothelium and is likely to be involved in regulating the traffic of leucocytes and tumor cells to lymph nodes
• The lymphatic vasculature forms a second circulatory system that drains extracellular fluid from the tissues and provides an exclusive environment in which immune cells can encounter and respond to foreign antigen
• A number of molecules have been identified as markers for lymphatic endothelium which include LYVE1, PALE, VEGFR3, and podoplanin
• Diseases associated with LYVE1 dysfunction includes Complete Androgen Insensitivity Syndrome.